Axatilimab
Monoclonal antibody
Evidence outlook
Approved: Chronic Graft-versus-Host Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Company guidance: data expected early 2028 (Incyte, 29 Oct 2026). “A Phase 3 trial evaluating axatilimab in combination with corticosteroids as an initial treatment in patients with chronic GVHD is ongoing, with results anticipated in early 2028.” Source ↗
Company guidance: topline data expected early 2028 (Syndax, 2 Nov 2026). “The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06821542 NCT06821542 · Chronic Graft-versus-Host Disease Registry: NCT06821542 | 3 | Objective Response (OR) at 6 months 2028-05-31 | In progress: results expected 31 May 2028 | not yet graded | link ↗ |
View 2 more trials
NCT06263478 NCT06263478 · Chronic Graft-versus-Host Disease All 21 patients received axatilimab in an open-label, single-group design with no randomization, no blinding and no comparator arm, so the response rate cannot be compared against anything. The primary endpoint is a clinical response rate by the 2014 NIH consensus criteria, but the small size and uncontrolled design limit what it can show. Registry: NCT06263478 | 3 | Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (up to the end of Cycle 6 (up to 168 days)) 2025-08-06 | Overall Response Rate (ORR) in the First 6 Treatment Cycles, as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (up to the end of Cycle 6 (up to 168 days)): Axatilimab 0.3 mg/kg IV Q2W 71.4 percentage of participants (95% CI 47.8 to 88.7) | Weak signal | link ↗ |
AGAVE-201 NCT04710576 · Chronic Graft-versus-Host Disease Registry: NCT04710576 | 2 | Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD) (First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks)) 2023-04-07 | Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD) (First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks)): Axatilimab 0.3 mg/kg Q2W 73.8 percentage of participants (95% CI 62.7 to 83) | Axatilimab 1 mg/kg Q2W 66.7 percentage of participants (95% CI 55.3 to 76.8) | Axatilimab 3 mg/kg Q4W 50 percentage of participants (95% CI 38.6 to 61.4) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other CSF-1R drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Axatilimab: this drug | Approved | Monoclonal antibody | CSF-1R | Weak signal | Featured results are non-efficacy only in this race | |
| Belumosudil | Approved | Small molecule | Rho-associated kinase (ROCK, pan) | Weak signal | NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants | |
| Ibrutinib | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Jakafi) | Approved | Small molecule | JAK1/2 | Partial signal | NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33) | |
| Enrupatinib | Phase 2(overall) | Small molecule | CSF-1R | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Axatilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (5)
January 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (3)
May 2028 (1)
What to watch
August 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (2)
2030 (1)
May 2030 (1)
What to watch
2031 (2)
2033 (1)
December 2033 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent